The ELANE Knockout 143B Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human 143B osteosarcoma cell line, engineered to disrupt the ELANE gene encoding neutrophil elastase. This polyclonal pool provides a versatile loss-of-function model for studying the contributions of this serine protease in a non-hematopoietic cancer background. The heterogeneous composition allows researchers to examine the collective impact of ELANE disruption on cellular phenotypes without the constraints of clonal selection, offering a robust tool for functional genomics and phenotypic screening.
The 143B host cell line is a well-characterized model of human osteosarcoma, distinguished by its high tumorigenicity and metastatic potential. Originally derived from a primary osteosarcoma, 143B cells are widely employed in oncology research to dissect mechanisms of tumor progression, invasion, and metastasis. Knockout of ELANE in this aggressive cancer cell line enables the investigation of neutrophil elastase functions beyond its classical role in innate immunity, particularly in the context of bone tumor biology and the metastatic cascade.
Neutrophil elastase, encoded by ELANE, is a serine protease integral to innate immune defense, where it degrades extracellular matrix components and bacterial proteins within neutrophil granules. Its expression is transcriptionally regulated by C/EBP alpha, PU.1, and granulopoiesis signaling via G-CSF. The protease is tightly controlled by endogenous inhibitors including alpha-1 antitrypsin (SERPINA1), secretory leukocyte peptidase inhibitor (SLPI), and Elafin. Upon activation, neutrophil elastase processes cytokines and activates other proteases, linking it to neutrophil degranulation and the formation of neutrophil extracellular traps. In the knockout model, disruption of ELANE abrogates this proteolytic activity, eliminating downstream signaling events mediated by these molecular interactions.
Expression of neutrophil elastase in osteosarcoma cells may influence tumor cell behavior by remodeling the extracellular matrix, modulating inflammatory signals, or interacting with serpin inhibitors like SERPINA1, which are often dysregulated in cancer. The ELANE knockout in 143B cells provides a unique system to explore non-canonical roles of this protease in tumorigenesis, including potential contributions to cell migration, invasion, and the establishment of metastases. By eliminating elastase activity, researchers can delineate its specific effects on oncogenic pathways and the tumor microenvironment, with implications for understanding how inflammation-driven proteolysis contributes to osteosarcoma progression.
This knockout cell pool is suitable for a broad range of experimental applications, including drug testing for elastase inhibitors, functional studies of gene networks via RT-qPCR and Western blotting, and phenotypic analyses such as cell proliferation, migration, and invasion assays. In vivo studies using xenograft models can assess the impact of ELANE deficiency on tumor growth and metastasis. Additionally, researchers can use these cells to investigate the interplay between neutrophil elastase and serpin inhibitors in a cancer setting. For further information, please contact Ascent Research.
